Amyloidosis: Heterogeneous group of diseases characterized by extracellular accumulation of abnormal fibrillar protein deposits (amyloid)
Cardiac involvement can result in infiltrative cardiomyopathy
IMAGING
General Features
Echocardiographic Findings
Nuclear Medicine Findings
CT Findings
MR Findings
Imaging Recommendations
CT Findings
DIFFERENTIAL DIAGNOSIS
PATHOLOGY
General Features
Staging, Grading, & Classification
Gross Pathologic & Surgical Features
Microscopic Features
CLINICAL ISSUES
Presentation
Demographics
Natural History & Prognosis
Treatment
DIAGNOSTIC CHECKLIST
Consider
Selected References
Falk RH: Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end? Eur Heart J. ePub, 2019
Tang CX et al: Cardiovascular magnetic resonance imaging for amyloidosis: the state-of-the-art. Trends Cardiovasc Med. 29(2):83-94, 2019
Rajiah P et al: Update on the role of cardiac magnetic resonance in acquired nonischemic cardiomyopathies. J Thorac Imaging. 31(6):348-66, 2016
Banypersad SM et al: T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 36(4):244-51, 2015
Fontana M et al: Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 132(16):1570-9, 2015
Treibel TA et al: Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. J Cardiovasc Comput Tomogr. 9(6):585-92, 2015
Dungu JN et al: CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 7(2):133-42, 2014
Falk RH et al: How to image cardiac amyloidosis. Circ Cardiovasc Imaging. 7(3):552-62, 2014
White JA et al: CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging. 7(2):143-56, 2014
Bokhari S et al: (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 6(2):195-201, 2013
Karamitsos TD et al: Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 6(4):488-97, 2013
Mongeon FP et al: Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovasc Imaging. 5(9):897-907, 2012
Wassmuth R et al: Prognostic impact of T2-weighted CMR imaging for cardiac amyloidosis. Eur Radiol. 21(8):1643-50, 2011
Austin BA et al: Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging. 2(12):1369-77, 2009
Vogelsberg H et al: Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 51(10):1022-30, 2008
vanden Driesen RI et al: MR findings in cardiac amyloidosis. AJR Am J Roentgenol. 186(6):1682-5, 2006
Falk RH: Diagnosis and management of the cardiac amyloidoses. Circulation. 112(13):2047-60, 2005
Kwong RY et al: Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 111(2):122-4, 2005
Maceira AM et al: Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 111(2):186-93, 2005
Dispenzieri A et al: Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 22(18):3751-7, 2004
Amyloidosis: Heterogeneous group of diseases characterized by extracellular accumulation of abnormal fibrillar protein deposits (amyloid)
Cardiac involvement can result in infiltrative cardiomyopathy
IMAGING
General Features
Echocardiographic Findings
Nuclear Medicine Findings
CT Findings
MR Findings
Imaging Recommendations
CT Findings
DIFFERENTIAL DIAGNOSIS
PATHOLOGY
General Features
Staging, Grading, & Classification
Gross Pathologic & Surgical Features
Microscopic Features
CLINICAL ISSUES
Presentation
Demographics
Natural History & Prognosis
Treatment
DIAGNOSTIC CHECKLIST
Consider
Selected References
Falk RH: Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end? Eur Heart J. ePub, 2019
Tang CX et al: Cardiovascular magnetic resonance imaging for amyloidosis: the state-of-the-art. Trends Cardiovasc Med. 29(2):83-94, 2019
Rajiah P et al: Update on the role of cardiac magnetic resonance in acquired nonischemic cardiomyopathies. J Thorac Imaging. 31(6):348-66, 2016
Banypersad SM et al: T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 36(4):244-51, 2015
Fontana M et al: Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 132(16):1570-9, 2015
Treibel TA et al: Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. J Cardiovasc Comput Tomogr. 9(6):585-92, 2015
Dungu JN et al: CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 7(2):133-42, 2014
Falk RH et al: How to image cardiac amyloidosis. Circ Cardiovasc Imaging. 7(3):552-62, 2014
White JA et al: CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging. 7(2):143-56, 2014
Bokhari S et al: (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 6(2):195-201, 2013
Karamitsos TD et al: Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 6(4):488-97, 2013
Mongeon FP et al: Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovasc Imaging. 5(9):897-907, 2012
Wassmuth R et al: Prognostic impact of T2-weighted CMR imaging for cardiac amyloidosis. Eur Radiol. 21(8):1643-50, 2011
Austin BA et al: Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging. 2(12):1369-77, 2009
Vogelsberg H et al: Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 51(10):1022-30, 2008
vanden Driesen RI et al: MR findings in cardiac amyloidosis. AJR Am J Roentgenol. 186(6):1682-5, 2006
Falk RH: Diagnosis and management of the cardiac amyloidoses. Circulation. 112(13):2047-60, 2005
Kwong RY et al: Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 111(2):122-4, 2005
Maceira AM et al: Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 111(2):186-93, 2005
Dispenzieri A et al: Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 22(18):3751-7, 2004